Movement disorders:PM2.5,或可诱发帕金森病

2022-08-31 Freeman MedSci原创

M2.5触发了α-Syn的病理学和PD的发病

帕金森病(PD)是第二种最常见的神经退行性疾病,影响着全世界400多万人。在病理学上,帕金森病的特点是黑质(SN)旁的多巴胺能神经元选择性地退化,并在剩余的神经元中形成路易体。路易体的主要蛋白成分是聚集的α-synuclein(α-Syn)。

 

图1: 论文封面图

有趣的是,α-Syn病理的空间进展在PD大脑中遵循一种刻板的模式。病理首先出现在嗅球(OB)和舌咽和迷走神经的背侧运动核,然后扩散到中脑和前脑。越来越多的证据表明,病理性α-Syn经历了细胞间的传递,并作为模板诱导可溶性α-Syn的聚集,导致整个大脑的病理放大。PD的病因很复杂,涵盖了多种互动的遗传和环境风险因素。PD的环境因素包括杀虫剂、重金属、病毒、空气污染等等。

多项流行病学研究发现,接触空气污染与PD的发病和进展高度相关。细颗粒物(PM2.5)是一种常见的空气污染,其颗粒的空气动力学直径≤2.5微米。最近,PM2.5对中枢神经系统的影响,特别是对PD发病的影响,正引起越来越多的关注。一项基于人口的纵向队列研究发现,接触PM2.5会显著增加PD的发病率。

令人震惊的是,长期暴露于高水平的空气污染会导致α-Syn在人脑中的积累,并增加脑脊液中低聚α-Syn的水平。空气污染暴露也会诱发儿童和相对年轻的成年人的OB内的α-Syn病理。

此外,生活在墨西哥城污染区的儿童患嗅觉障碍的风险增加,这是PD的早期症状之一。以前的研究表明,PM2.5会诱发神经炎症和自噬抑制,这被认为会促进神经元损伤。然而,目前仍不清楚PM2.5是否直接引发了α-Syn的聚集和黑质多巴胺能通路的退化,而这正是PD的组织病理学特征。

藉此,武汉大学人民医院的Xin Yuan等评估了PM2.5对α-Syn聚集的影响。

图2:论文结果图

他们发现,PM2.5在体外和体内都能促进α-Syn的纤维化。此外,与纯α-Syn纤维化相比,PM2.5诱导的α-Syn纤维化表现出更强的播种活性和神经毒性。

在表达人类A53T突变体α-Syn的转基因小鼠(α-Syn A53T小鼠)中,脑内注射或鼻内灌注PM2.5会加重PD样病变和运动障碍。

这些结果表明,PM2.5触发了α-Syn的病理学和PD的发病。细颗粒物引发α-Synuclein纤维化和帕金森样神经变性。


原文出处:
Yuan X, Yang Y, Liu C, et al. Fine Particulate Matter Triggers α‐Synuclein Fibrillization and Parkinson‐like Neurodegeneration. _Movement Disorders_. Published online August 22, 2022:mds.29181. doi:[10.1002/mds.29181](https://doi.org/10.1002/mds.29181)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1878578, encodeId=d62118e85787e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Dec 07 12:13:50 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013953, encodeId=535d20139535c, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 04 06:13:50 CST 2023, time=2023-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784543, encodeId=f0891e84543e3, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Mon Nov 28 13:13:50 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077722, encodeId=7b3420e77224b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Mar 02 10:13:50 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738154, encodeId=146b1e38154f9, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sun Nov 20 11:13:50 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265035, encodeId=09ae126503572, content=<a href='/topic/show?id=9574144034a' target=_blank style='color:#2F92EE;'>#PM2.5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14403, encryptionId=9574144034a, topicName=PM2.5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Tue Aug 30 13:13:50 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
    2022-12-07 anminleiryan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1878578, encodeId=d62118e85787e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Dec 07 12:13:50 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013953, encodeId=535d20139535c, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 04 06:13:50 CST 2023, time=2023-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784543, encodeId=f0891e84543e3, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Mon Nov 28 13:13:50 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077722, encodeId=7b3420e77224b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Mar 02 10:13:50 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738154, encodeId=146b1e38154f9, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sun Nov 20 11:13:50 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265035, encodeId=09ae126503572, content=<a href='/topic/show?id=9574144034a' target=_blank style='color:#2F92EE;'>#PM2.5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14403, encryptionId=9574144034a, topicName=PM2.5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Tue Aug 30 13:13:50 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1878578, encodeId=d62118e85787e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Dec 07 12:13:50 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013953, encodeId=535d20139535c, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 04 06:13:50 CST 2023, time=2023-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784543, encodeId=f0891e84543e3, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Mon Nov 28 13:13:50 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077722, encodeId=7b3420e77224b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Mar 02 10:13:50 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738154, encodeId=146b1e38154f9, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sun Nov 20 11:13:50 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265035, encodeId=09ae126503572, content=<a href='/topic/show?id=9574144034a' target=_blank style='color:#2F92EE;'>#PM2.5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14403, encryptionId=9574144034a, topicName=PM2.5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Tue Aug 30 13:13:50 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
    2022-11-28 cmsvly
  4. [GetPortalCommentsPageByObjectIdResponse(id=1878578, encodeId=d62118e85787e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Dec 07 12:13:50 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013953, encodeId=535d20139535c, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 04 06:13:50 CST 2023, time=2023-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784543, encodeId=f0891e84543e3, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Mon Nov 28 13:13:50 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077722, encodeId=7b3420e77224b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Mar 02 10:13:50 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738154, encodeId=146b1e38154f9, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sun Nov 20 11:13:50 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265035, encodeId=09ae126503572, content=<a href='/topic/show?id=9574144034a' target=_blank style='color:#2F92EE;'>#PM2.5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14403, encryptionId=9574144034a, topicName=PM2.5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Tue Aug 30 13:13:50 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1878578, encodeId=d62118e85787e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Dec 07 12:13:50 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013953, encodeId=535d20139535c, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 04 06:13:50 CST 2023, time=2023-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784543, encodeId=f0891e84543e3, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Mon Nov 28 13:13:50 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077722, encodeId=7b3420e77224b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Mar 02 10:13:50 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738154, encodeId=146b1e38154f9, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sun Nov 20 11:13:50 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265035, encodeId=09ae126503572, content=<a href='/topic/show?id=9574144034a' target=_blank style='color:#2F92EE;'>#PM2.5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14403, encryptionId=9574144034a, topicName=PM2.5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Tue Aug 30 13:13:50 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1878578, encodeId=d62118e85787e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Dec 07 12:13:50 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013953, encodeId=535d20139535c, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 04 06:13:50 CST 2023, time=2023-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784543, encodeId=f0891e84543e3, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Mon Nov 28 13:13:50 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077722, encodeId=7b3420e77224b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Mar 02 10:13:50 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738154, encodeId=146b1e38154f9, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sun Nov 20 11:13:50 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265035, encodeId=09ae126503572, content=<a href='/topic/show?id=9574144034a' target=_blank style='color:#2F92EE;'>#PM2.5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14403, encryptionId=9574144034a, topicName=PM2.5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Tue Aug 30 13:13:50 CST 2022, time=2022-08-30, status=1, ipAttribution=)]

相关资讯

JAMA Netw Open:做好这两点,帕金森病患者全因死亡风险骤降65%!

 JAMA Netw Open:饮食和身体活动与帕金森病成人全因死亡率的关系

Movement disorders:大脑代谢与前驱和早期帕金森病中的多巴胺能失调有关

在前驱期和早期PD阶段,与多巴胺能神经支配有关的各个脑区的代谢反应的轨迹是不同的。

Movement disorders:湘雅医院:狗狗嗅一嗅,就能诊断帕金森病?

使用嗅探犬进行测试可能是一种有用的、无创的、快速的和具有成本效益的方法

Movement disorders:帕金森病的运动和认知代谢网络之间的关系

通过delta量化的PDRP优势,可以检测出PD患者的功能障碍从运动网络向认知网络的扩散

Movement disorders:葡萄糖苷酶变体携带者和家族性帕金森病的性别频率差异

GBA PD总体上存在的男性性别优势在GBA变异的严重程度上并不一致,

JAMA子刊:高翔教授发现吃得对会运动,帕金森死亡率能降一半!

无论是健康饮食还是积极锻炼,都能充分保护帕金森患者的寿命。

拓展阅读

AAN 2024大会盛况回顾,带您领略神经病学新高度!

作为神经科医生,您一定对AAN 2024年大会充满期待。我们为您精心整理了大会内容解读,包括最新研究成果、临床实践经验和未来发展趋势等,让您足不出户就能领略到大会的精彩盛况!点击立即查看别错过!

AAN 2024:突触核蛋白皮肤活检在帕金森病的初步诊断的临床实践

帕金森病早期准确诊断是一项尚未满足的重大需求,这对于早期干预和预后改善有着重要的影响。

Nature Medicine:重塑帕金森病治疗前景:Prasinezumab在早期帕金森病快速进展亚型中的疗效分析

文章探讨了Prasinezumab这种单克隆抗体在早期帕金森病中的潜在的治疗作用。

【帕金森病专题分享】探索帕金森病进展及诊疗全攻略

帕金森病日来临之际,我们特别推出了帕金森病专题系列文章。无论你是初入此领域的新手,还是经验丰富的专家,这里都有你需要的知识和信息。点击立即阅读,共同提升帕金森病诊疗水平!

话题:帕金森病的真相你了解多少?

我们欢迎各位老师,学者们在下方评论区共同探讨帕金森病的各个方面,包括但不限于:帕金森病的介绍、早期症状、体征、预防等都可一起分享出来。

好文推荐 | 帕金森病睡眠障碍结构特征及其影响因素的临床研究

探讨帕金森病(PD)患者睡眠障碍的发生率、睡眠结构特征、影响因素。

2024 NICE 诊断指南:帕金森病远程监测设备 [DG51]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2024-01-25

2023 NICE 技术鉴定指南:左旋多巴/卡比多巴组合治疗伴有运动症状的晚期帕金森病[TA934]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-11-29

帕金森病患者睡眠障碍评估与护理干预的最佳证据总结

浙江中医药大学护理学院 · 2023-08-10

早中期帕金森病患者运动管理的最佳证据总结

山东第一医科大学附属省立医院老年神经内科 · 2023-05-10